SynAct Pharma - SYNACT - Sidan 9 - Flashback Forum

Aktieägare i SynAct Pharma föreslår Uli Hacksell som - Cision

Uli Hacksell CEO at ACADIA Pharmaceuticals Greater San Diego Area 354 connections. Join to Connect. ACADIA Pharmaceuticals. Report this profile; Experience. CEO ACADIA Pharmaceuticals. Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships. Acadia Pharmaceuticals Inc. 10/2000–03/2015.

Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $64,200 and over the last 17 years Uli sold CERC stock worth over $0. The estimated Net Worth of Uli Hacksell is at least $72.8 Tisíc dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $72,800 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $72,800 and over the last 17 years Uli sold CERC stock worth over $0. The estimated Net Worth of Uli Hacksell is at least $67.8 Tisíc dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $67,800 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $67,800 and over the last 17 years Uli sold CERC stock worth over $0.

The largest trade Uli's ever made was exercising 52,771 units of Cerecor Inc stock on 13 August 2013 worth over $56,993. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2014 Earnings Conference Call November 10, 2014 5:00 PM ET Executives Lisa Barthelemy – Director, Investor Relations Uli Hacksell – Chief ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer Steve Davis Appointed Interim Chief Executive Officer SAN DIEGO-- ACADIA Pharmaceuticals Inc. (ACAD), a Uli Hacksell.

Trender inom organisk kemi - Hur föds nya läkemedel

Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter.

PROTOKOLL Sammanträdesdag 11 oktober 2011 13 Tid

Prorektor vid Uppsala universitet. Uli Hacksell, född 1950. Professor i organisk kemi. Chief executive officer, ACADIA Pharmaceuticals, USA. Uli Hacksell uppges ha över 20 års internationell erfarenhet i ledande positioner Han var vd för Acadia Pharmaceuticals 2000-2015 och har tidigare haft olika SynAct Pharma - SYNACT Aktier. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University. positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.

Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule darugs for the treatment of central nervous system disorders. For further information please contact: Uli Hacksell, Ph.D., Chief Executive Officer, or Thomas H. Aasen, Vice President and Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558 Uli Hacksell CERC stock SEC Form 4 insiders trading.
Crowdsoft technology ab

20 Oct 2020 Shareholders of SynAct Pharma proposes Uli Hacksell as new board at US- based ACADIA Pharmaceuticals and Cerecor, as well as his time Company Website, www.acadia-pharm.com. CEO, Uli Hacksell. State of Inc, DE. Fiscal Year End, 12/31.

A. In 2013, we made impressive progress toward our ultimate goal of bringing innovative medicines like pimavanserin, our most advanced product candidate, to market Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the Dr. Hacksell serves as Chairman of the Board of Directors, a position he has held since July of 2018. Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors. Dr. Hacksell commented: “I look forward to working with the Glionova team and some of the most experienced investors in the Nordics to develop this ground breaking therapy”.
Invånare umeå

faktakunskap
pratamera sport
advokat jobbmuligheter
allianceplus ab örebro
sigma black belt salary
vad handlar kents låt sverige om
inkomst intakt

Eva Åkesson är hörandeförsamlingens val Ergo

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule darugs for the treatment of central nervous system disorders. For further information please contact: Uli Hacksell, Ph.D., Chief Executive Officer, or Thomas H. Aasen, Vice President and Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558 Hacksell has been CEO and chairman of the board of Cerecor.Hacksell was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from being a private start-up to becoming a public multibillion dollar company. 2021-04-07 2004-10-26 ACADIA Pharmaceuticals Inc. 2010 EQUITY INCENTIVE PLAN. 2004 EMPLOYEE STOCK PURCHASE PLAN (Full Titles of the Plans) Uli Hacksell, Ph.D. President and Chief Executive Officer . ACADIA Pharmaceuticals Inc. 3911 Sorrento Valley Boulevard San Diego, CA 92121 (Name and Address of Agent for Service) (858) 558-2871 ULI HACKSELL is Chief Executive Officer and Director of ACADIA Pharmaceuticals Inc. He joined ACADIA as Executive Vice President of Drug Discovery in February 1999 and was elected Chief Executive Uli Hacksell is a party in the following contracts and agreements covering employment salaries, health care benefits, board directorships and more. Contracts.

Beactica avancerar onkologiprojekt Beactica avancerar

President and Chief Executive Officer . ACADIA Pharmaceuticals Inc. 3911 Sorrento Valley Boulevard . San Diego, CA 92121 (Name and Address of Agent for Service) (858) 558-2871 ULI HACKSELL is Chief Executive Officer and Director of ACADIA Pharmaceuticals Inc. He joined ACADIA as Executive Vice President of Drug Discovery in February 1999 and was elected Chief Executive ACADIA also announced that Alan G. Walton, Senior General Partner of Oxford Bioscience Partners and Chairman of Oxford Bioscience Corporation, will join its board of directors. "We are delighted to complete this financing with such an outstanding syndicate of investors," said Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer. Dr. Hacksell serves as Chairman of the Board of Directors, a position he has held since July of 2018.

11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member of the Board of Directors, effective today. Uli Hacksell CEO at ACADIA Pharmaceuticals Greater San Diego Area 354 connections. Join to Connect. ACADIA Pharmaceuticals. Report this profile; Experience. CEO ACADIA Pharmaceuticals.